vs
Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and TOWER SEMICONDUCTOR LTD (TSEM). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $351.2M, roughly 1.4× TOWER SEMICONDUCTOR LTD). TOWER SEMICONDUCTOR LTD runs the higher net margin — 15.2% vs 6.8%, a 8.4% gap on every dollar of revenue. On growth, TOWER SEMICONDUCTOR LTD posted the faster year-over-year revenue change (-1.7% vs -1.7%).
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
Tower Semiconductor Ltd. is an Israeli company that manufactures integrated circuits using specialty process technologies, including SiGe, BiCMOS, Silicon Photonics, SOI, mixed-signal and RFCMOS, CMOS image sensors, non-imaging sensors, power management (BCD), and non-volatile memory (NVM) as well as MEMS capabilities. Tower Semiconductor also owns 51% of TPSCo, an enterprise with Nuvoton Technology Corporation Japan (NTCJ).
MD vs TSEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $493.8M | $351.2M |
| Net Profit | $33.7M | $53.4M |
| Gross Margin | — | 24.8% |
| Operating Margin | 9.9% | 15.7% |
| Net Margin | 6.8% | 15.2% |
| Revenue YoY | -1.7% | -1.7% |
| Net Profit YoY | 10.5% | 4.4% |
| EPS (diluted) | $0.40 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $493.8M | — | ||
| Q3 25 | $492.9M | — | ||
| Q2 25 | $468.8M | — | ||
| Q1 25 | $458.4M | — | ||
| Q4 24 | $502.4M | — | ||
| Q3 24 | $511.2M | — | ||
| Q2 24 | $504.3M | $351.2M | ||
| Q1 24 | $495.1M | — |
| Q4 25 | $33.7M | — | ||
| Q3 25 | $71.7M | — | ||
| Q2 25 | $39.3M | — | ||
| Q1 25 | $20.7M | — | ||
| Q4 24 | $30.5M | — | ||
| Q3 24 | $19.4M | — | ||
| Q2 24 | $-153.0M | $53.4M | ||
| Q1 24 | $4.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 24.8% | ||
| Q1 24 | — | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 13.8% | — | ||
| Q2 25 | 12.8% | — | ||
| Q1 25 | 7.0% | — | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | -31.3% | 15.7% | ||
| Q1 24 | 3.2% | — |
| Q4 25 | 6.8% | — | ||
| Q3 25 | 14.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | 4.5% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | -30.3% | 15.2% | ||
| Q1 24 | 0.8% | — |
| Q4 25 | $0.40 | — | ||
| Q3 25 | $0.84 | — | ||
| Q2 25 | $0.46 | — | ||
| Q1 25 | $0.24 | — | ||
| Q4 24 | $0.37 | — | ||
| Q3 24 | $0.23 | — | ||
| Q2 24 | $-1.84 | $0.48 | ||
| Q1 24 | $0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $375.2M | $265.3M |
| Total DebtLower is stronger | $570.5M | — |
| Stockholders' EquityBook value | $865.9M | $2.5B |
| Total Assets | $2.2B | $3.0B |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $375.2M | — | ||
| Q3 25 | $340.1M | — | ||
| Q2 25 | $224.7M | — | ||
| Q1 25 | $99.0M | — | ||
| Q4 24 | $229.9M | — | ||
| Q3 24 | $103.8M | — | ||
| Q2 24 | $19.4M | $265.3M | ||
| Q1 24 | $8.0M | — |
| Q4 25 | $570.5M | — | ||
| Q3 25 | $577.2M | — | ||
| Q2 25 | $583.9M | — | ||
| Q1 25 | $590.5M | — | ||
| Q4 24 | $597.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $865.9M | — | ||
| Q3 25 | $890.7M | — | ||
| Q2 25 | $833.8M | — | ||
| Q1 25 | $789.2M | — | ||
| Q4 24 | $764.9M | — | ||
| Q3 24 | $732.5M | — | ||
| Q2 24 | $706.5M | $2.5B | ||
| Q1 24 | $856.2M | — |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.0B | $3.0B | ||
| Q1 24 | $2.2B | — |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $114.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.39× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $114.1M | — | ||
| Q3 25 | $137.3M | — | ||
| Q2 25 | $137.2M | — | ||
| Q1 25 | $-117.5M | — | ||
| Q4 24 | $133.0M | — | ||
| Q3 24 | $91.8M | — | ||
| Q2 24 | $107.0M | — | ||
| Q1 24 | $-125.2M | — |
| Q4 25 | 3.39× | — | ||
| Q3 25 | 1.91× | — | ||
| Q2 25 | 3.49× | — | ||
| Q1 25 | -5.66× | — | ||
| Q4 24 | 4.36× | — | ||
| Q3 24 | 4.72× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -31.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
TSEM
Segment breakdown not available.
